The coagulopathy of cirrhosis: Myth or reality?

Hepatology

Volumn 41, Issue 3, 2005, Pages 434-435

  Bosch, Jaime ^a,b   Reverter, Juan Carlos ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; PROTEIN C; THROMBIN; THROMBOMODULIN;

BLEEDING TENDENCY; DISEASE SEVERITY; EDITORIAL; FIBRINOLYSIS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; PARTIAL THROMBOPLASTIN TIME; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTOPENIA;

BLOOD COAGULATION DISORDERS; FACTOR VIIA; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; PARTIAL THROMBOPLASTIN TIME; THROMBIN;

EID: 14244260492     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20639     Document Type: Editorial

References (13)

1. Hedner U, Erhardtsen E. Hemostatic disorders in liver diseases. In: Schiff ER et al., eds. Schiffs Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins, 2003:625-636.
2. Francis RB, Jr., Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984;14:460-465.
3. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. HEPATOLOGY 2003;38:230-237.
4. Bosch J, D'Amico G, García-Pagán JC. Portal hypertension. In: Schiff ER et al., eds. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins, 2003:429-486.
5. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001;33:464-470.
6. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. HEPATOLOGY 2005;41:553-558.
7. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
8. Erlinger S, Benhamou P. Cirrhosis: clinical aspects. In: McIntyre N et al., eds. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1991:380-390.
9. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-874.
10. Ordinas A, Escolar G, Cirera I, Vinas M, Cobo F, Bosch J, etal. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit. studies under flow conditions. HEPATOLOGY 1996;24:1137-1142.
11. Burroughs AK, Bosch J. Clinical manifestations and management of bleeding episodes in cirrhotics: In: McIntyre N, et al., eds. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1991:408-425.
12. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez AJ, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004;127:1123-1130.
13. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenrerology 2001;121:131-139.